BC
BCTX.US Briacell Therapeutics Corp
- Market cap
- USD 29.6M
- P/E
- -
- P/B
- 1.87x
- ROE
- -212.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jul 2026.
Is BCTX.US undervalued?
Graham numberThe Graham number of Briacell Therapeutics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Briacell Therapeutics Corp fundamental analysis
No fundamental analysis for Briacell Therapeutics Corp yet.
Briacell Therapeutics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. I…
Full company profileBriacell Therapeutics Corp financial statements
Briacell Therapeutics Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 |
| Gross Profit | -289.00 | -16.9K | -18.8K | -18.7K | -15.6K | -15.1K | -12.0K | -82.6K | -107K | -118K |
| Operating Income | -3.21M | -4.97M | -6.25M | -5.28M | -8.72M | -19.6M | -23.3M | -33.3M | -27.2M | -35.6M |
| EBITDA | -3.22M | -5.37M | -5.77M | -4.82M | -17.2M | -34.4M | -23.3M | -4.85M | -27.1M | -35.5M |
| Net Income | -3.22M | -5.41M | -5.82M | -4.94M | -17.3M | -34.4M | -20.3M | -4.79M | -26.3M | -34.9M |
| EPS | -142 | -190 | -151 | -104 | -57 | -33 | -19 | -4.37 | -14 | -6.97 |
| Balance Sheet | ||||||||||
| Total Assets | 1.64M | 2.28M | 445K | 522K | 72.5M | 54.6M | 27.2M | 5.87M | 21.7M | 23.6M |
| Total Liabilities | 886K | 1.34M | 1.13M | 4.12M | 38.0M | 41.4M | 30.9M | 8.56M | 4.32M | 8.02M |
| Shareholders' Equity | 750K | 945K | -689K | -3.60M | 34.6M | 13.2M | -3.78M | -2.38M | 17.9M | 16.4M |
| Cash & Short-term Investments | 1.62M | 1.75M | 157K | 21.2K | 71.6M | 52.6M | 21.3M | 862K | 17.9M | 20.5M |
| Total Debt | - | 1.12M | 323K | 250K | 32.5K | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.91M | -4.95M | -5.12M | -1.55M | -9.89M | -15.9M | -23.7M | -24.1M | -28.2M | -28.3M |
| Capital Expenditure | 4.00 | 3.00 | 5.02 | 0.00 | 4.27 | 0.00 | 3.59 | 457K | 3.08 | 127K |
| Free Cash Flow | -1.91M | -4.95M | -5.12M | -1.55M | -9.89M | -15.9M | -23.7M | -24.6M | -28.2M | -28.8M |
| Ratios | ||||||||||
| ROE | -428.9% | -572.2% | - | - | -49.9% | -259.8% | - | - | -147.2% | -212.8% |
| ROA | -196.6% | -236.7% | -1,308.4% | -946.3% | -23.8% | -63.0% | -74.7% | -81.6% | -121.5% | -148.0% |
| Debt to Equity | - | 1.19x | - | - | 0.00x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Briacell Therapeutics Corp dividends
Briacell Therapeutics Corp has not paid dividends in the last 10 fiscal years.
Last stock split: 1:10 on Aug 25, 2025.
Who owns Briacell Therapeutics Corp
- Insiders 0.14%
- Institutions 5.82%
- Public & others 94.05%
- Shares outstanding 8.73M
- Free float 7.96M
Top funds holding BCTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 3.23K | 0.04% | 0.00% | Aug 2026 |
Top institutions holding BCTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Cable Car Capital LLC | 217K | 2.49% | 0.00% | Jun 2026 |
| Sabby Management LLC | 80.7K | 0.93% | +9.21% | Jun 2026 |
| Iridian Asset Management LLC | 65.0K | 0.75% | 0.00% | Jun 2026 |
| UBS Group AG | 43.6K | 0.50% | +278.15% | Jun 2026 |
| HRT FINANCIAL LLC | 34.9K | 0.40% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 26.5K | 0.30% | 0.00% | Jun 2026 |
| LuminArx Capital Management LP | 15.0K | 0.17% | 0.00% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 1.80K | 0.02% | +124.81% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.03K | 0.01% | -65.81% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 450.00 | 0.01% | -1.10% | Jun 2026 |
| Royal Bank of Canada | 289.00 | 0.00% | 0.00% | Jun 2026 |
| Hanson Mcclain Inc | 100.00 | 0.00% | 0.00% | Jun 2026 |
| SSA SWISS ADVISORS AG | 37.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 34.00 | 0.00% | +385.71% | Jun 2026 |
| TD Waterhouse Canada Inc | 19.00 | 0.00% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 16.00 | 0.00% | 0.00% | Jun 2026 |
| HHM Wealth Advisors, LLC | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 1.00 | 0.00% | 0.00% | Jun 2026 |
Briacell Therapeutics Corp company profile
- Company name
- Briacell Therapeutics Corp
- Ticker
- BCTX.US
- ISIN
- CA1079303071
- Exchange
- USA Stocks
- Listed since
- Feb 24, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 31
- Fiscal year end
- July
- Address
- Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1
- Phone
- 604-921-1810
- Website
- briacell.com
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.
Briacell Therapeutics Corp management
5- Dr. William V. Williams FCPA, M.D.CEO, President & Director · born 1955
- Mr. Gadi Levin B.Com., C.A., CPA, M.B.A.CFO & Corporate Secretary · born 1973
- Dr. Miguel A. Lopez-Lago Ph.D.Chief Scientific Officer · born 1969
- Dr. Giuseppe Del Priore M.D., M.P.H.Chief Medical Officer · born 1962
- Dr. Charles Louis Wiseman FACP, M.D.Founder, Principal Research Advisor & Member of Scientific Advisory Board · born 1946